Anti-dsDNA and anti-Sm antibodies do not predict damage in systemic lupus erythematosus

Lupus

Volumn 15, Issue 5, 2006, Pages 285-291

  Prasad, R ^a   Ibanez D ^a   Gladman, D ^a   Urowitz, M ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

Anti dsDNA; Anti Sm; Damage; Outcomes; SLE

Indexed keywords

CORTICOSTEROID; DNA ANTIBODY; DOUBLE STRANDED DNA ANTIBODY; SINGLE STRANDED MUTAGENIC DNA ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE DURATION; DNA DAMAGE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MUSCULOSKELETAL DISEASE; NEUROPSYCHIATRY; OUTCOME ASSESSMENT; OUTCOME VARIABLE; PREDICTOR VARIABLE; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADRENAL CORTEX HORMONES; ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGE FACTORS; AGE OF ONSET; ANTIBODIES, ANTINUCLEAR; ASIAN CONTINENTAL ANCESTRY GROUP; CARIBBEAN REGION; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 33744790284     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203306lu2302oa     Document Type: Article

References (31)

1. Alba P, Bento L, Cuadrado MJ et al. Anti-dsDNA, anti-Sm antibodies, and the lupus anticoagulant: significant factors associated with lupus nephritis. Ann Rheum Dis 2003; 62: 556-560.
2. Isenberg DA, Garton M, Reichlin MW, Reichlin M. Long-term follow-up of autoantibody profiles in black female lupus patients and clinical comparison with Caucasian and Asian patients. Br J Rheumatol 1997; 36: 229-233.
3. Ravirajan CT, Rowse L, MacGowan JR, Isenberg DA. An analysis of clinical disease activity and nephritis-associated serum autoantibody profiles in patients with systemic lupus erythematosus: a cross-sectional study. Rheumatology 2001; 40: 1405-1412.
4. Swaak AJ, Groenwold J, Bronsveld W. Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus. Ann Rheum Dis 1986; 45: 359-366.
5. ter Borg EJ, Horst G, Hummel EJ, Limburg PC, Kallenberg CG. Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. Arthritis Rheum 1990; 33: 634-643.
6. Janwityanuchit S, Verasertniyom O, Vanichapuntu M, Vatanasuk M. Anti-Sm: its predictive value in systemic lupus erythematosus. Clin Rheumatol 1993; 12: 350-353.
7. Winfield JB, Brunner CM, Koffler D. Serologic studies in patients with systemic lupus erythematosus and central nervous system dysfunction. Arthritis Rheum 1978; 21: 289-294.
8. Riboldi P, Gerosa M, Moroni G et al. Anti-DNA antibodies: a diagnostic and prognostic tool for systemic lupus erythematosus? Autoimmunity 2005; 38: 39-45.
9. Neogi T, Gladman DD, Ibanez D, Urowitz MB. Anti-dsDNA antibody testing by Farr and ELISA techniques are not equivalent. Arthritis Rheum 2003; 48 (9 Suppl): S582.
10. Gladman D, Ginzler E, Goldsmith C et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996; 39: 363-269.
11. Gladman DD, Goldsmith CH, Urowitz MB et al. The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison. J Rheumatol 2000; 27: 373-376.
12. Ibanez D, Gladman D, Urowitz MB. Adjusted mean Systemic Lupus Erythematosus Disease Activity Index-2K is a predictor of outcome in SLE. J Rheumatol 2005; 32: 824-827.
13. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
14. Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002; 29: 288-291.
15. Ibanez D, Urowitz MB, Gladman DD. Summarizing disease features over time: I. Adjusted mean SLEDAI derivation and application to an index of disease activity in lupus. J Rheumatol 2003; 30: 1977-1982.
16. Borchers AT, Keen CL, Shoenfeld Y, Gershwin ME. Surviving the butterfly and the wolf: mortality trends in systemic lupus erythematosus. Autoimmun Rev 2004; 3: 423-453.
17. Urowitz MB, Gladman DD. How to improve morbidity and mortality in systemic lupus erythematosus. Rheumatology 2000; 39: 237-243.
18. Alarcon GS, Roseman JM, McGwin G Jr et al. Systemic lupus erythematosus in three ethnic groups. XX. Damage as a predictor of further damage. Rheumatology 2004; 43: 202-205.
19. Gilboe IM, Kvien TK, Husby G. Disease course in systemic lupus erythematosus: changes in health status, disease activity, and organ damage after 2 years. J Rheumatol 2001; 28: 266-274.
20. Stoll T, Sutcliffe N, Klaghofer R, Isenberg DA. Do present damage and health perception in patients with systemic lupus erythematosus predict extent of future damage?: a prospective study. Ann Rheum Dis 2000; 59: 832-835.
21. Rahman P, Gladman DD, Urowitz MB, Hallett D, Tam LS. Early damage as measured by the SLICC/ACR Damage Index is a predictor of mortality in SLE. Lupus 2001; 10: 93-96.
22. Karlson E, Daltroy L, Lew R et al. Predictors of disease activity and organ damage in SLE. Arthritis Rheum 1994; 37 (Suppl): S199.
23. Straaton K, Alarcon GS, Roseman J et al. Determinants of disease damage in Hispanic (H), African-American (AA) and Caucasian (C) SLE patients. Arthritis Rheum 1996; 39: (Suppl): S111.
24. Yee CS, Hussein H, Skan J, Bowman S, Situnayake D, Gordon C. Association of damage with autoantibody profile, age, race, sex and disease duration in systemic lupus erythematosus. Rheumatology 2003; 42: 276-279.
25. Zonana-Nacach A, Camargo-Coronel A, Yanez P et al. Measurement of damage in 210 Mexican patients with systemic lupus erythematosus: relationship with disease duration. Lupus 1998; 7: 119-123.
26. Stoll T, Seifert B, Isenberg DA. SLICC/ACR Damage Index is valid, and renal and pulmonary organ scores are predictors of severe outcome in patients with systemic lupus erythematosus. Br J Rheumatol 1996; 35: 248-254.
27. Gorgos L, Goldman D, Petri M. The ACR/SLICC damage index in systemic lupus erythematosus. Arthritis Rheum 2005; 36: (Suppl): S68.
28. Zonana-Nacach A, Barr SG, Magder LS, Petri M. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 2000; 43: 1801-1808.
29. Mikdashi J, Handwerger B. Predictors of neuropsychiatric damage in systemic lupus erythematosus: data from the Maryland lupus cohort. Rheumatol (Oxford) 2004; 43: 1555-1560.
30. Gladman DD, Urowitz MB, Rahman P, Ibanez D, Tam LS. Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol 2003; 30: 1955-1959.
31. Bootsma H, Sponk P, Derksen R et al. Prevention of relapses in systemic lupus erythematosus. Lancet 1995; 345: 1595-1599.